[18F]SYN1与[18F]SYN2用于PET心肌灌注显像的临床前评价
本研究在正常Wistar大鼠中临床前评价两种新型PET心肌灌注显像示踪剂[18F]SYN1和[18F]SYN2,动态microPET显示两者均快速心肌摄取,但[18F]SYN2摄取更高且稳定,平均标准化摄取值3.8。生物分布研究证实[18F]SYN2心肌摄取高且稳定(15分钟3.02%ID/g,6小时2.79%ID/g),优于[18F]SYN1(15分钟1.84%ID/g,6小时0.32%ID/g)。[18F]SYN2具有有利的药效学和药代动力学特征,结果鼓励进一步临床研究。
要点
- [18F]SYN2心肌摄取高于[18F]SYN1且更稳定,平均标准化摄取值3.8。
- [18F]SYN2心肌生物分布15分钟3.02%ID/g、6小时2.79%ID/g,优于[18F]SYN1。
- 两者NOAEL均为2 mg/kg,[18F]SYN1人体有效剂量0.00714 mSv/MBq,[18F]SYN2为0.0109 mSv/MBq。
核心结论
- [18F]SYN2显示出有利的药效学和药代动力学特征,在microPET中可清晰显示心脏。
- 该化合物在正常大鼠研究中耐受良好,辐射暴露适中。
- 结果鼓励进一步在临床研究中探索[18F]SYN2。
研究设计与样本
- 在正常Wistar大鼠中开展的临床前研究,旨在表征两种潜在新型示踪剂[18F]SYN1和[18F]SYN2,评价哪个是更好的PET心肌灌注显像示踪剂候选者。
主要发现
- 动态microPET图像显示两种示踪剂均快速心肌摄取,但[18F]SYN2摄取更高且稳定,平均标准化摄取值3.8。
- 生物分布研究证实[18F]SYN2心肌摄取高且稳定(15分钟3.02%ID/g,6小时2.79%ID/g),而[18F]SYN1为15分钟1.84%ID/g、6小时0.32%ID/g。
- 剂量学研究中确定的关键器官为小肠和肾脏。
- [18F]SYN1人体估算有效剂量为0.00714 mSv/MBq,[18F]SYN2为0.0109 mSv/MBq。
- 两种候选物的测试剂量水平2 mg/kg被认为是未观察到有害作用剂量(NOAEL)。
关键数值与推荐
- [18F]SYN2结果更好,因此进一步临床前研究仅针对该示踪剂进行。
- 放射性配体结合实验显示68项实验中有3项显著反应:毒蕈碱乙酰胆碱M1和M2受体及钾通道hERG。
- 该化合物主要通过氧化性N-脱烷基化代谢,氟取代基未从分子上分离。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Positron emission tomography (PET) is now an established diagnostic method for myocardial perfusion imaging (MPI) in coronary artery disease, which is the main cause of death globally. The available tracers show several limitations, therefore, the 18F-labelled tracer is in high demand nowadays. The preclinical studies on normal Wistar rats aimed to characterise two potential, novel radiotracers, [18F]SYN1 and [18F]SYN2, to evaluate which is a better candidate for PET MPI cardiotracer. RESULTS: The dynamic microPET images showed rapid myocardial uptake for both tracers. However, the uptake was higher and also stable for [18F]SYN2, with an average standardized uptake value of 3.8. The biodistribution studies confirmed that [18F]SYN2 uptake in the cardiac muscle was high and stable (3.02%ID/g at 15 min and 2.79%ID/g at 6 h) compared to [18F]SYN1 (1.84%ID/g at 15 min and 0.32%ID/g at 6 h). The critical organs determined in dosimetry studies were the small intestine and the kidneys. The estimated effective dose for humans was 0.00714 mSv/MBq for [18F]SYN1 and 0.0109 mSv/MBq for [18F]SYN2. The tested dose level of 2 mg/kg was considered to be the No Observed Adverse Effect Level (NOAEL) for both candidates. The better results were achieved for [18F]SYN2, therefore, further preclinical studies were conducted only for this tracer. Radioligand binding assays showed significant responses in 3 from 68 assays: muscarinic acetylcholine M1 and M2 receptors and potassium channel hERG. The compound was mostly metabolised via an oxidative N-dealkylation, while the fluor substituent was not separated from the molecule. CONCLUSION: [18F]SYN2 showed a favourable pharmacodynamic and pharmacokinetic profile, which enabled a clear visualization of the heart in microPET. The compound was well-tolerated in studies in normal rats with moderate radiation exposure. The results encourage further exploration of [18F]SYN2 in clinical studies.
引用
- Krajewski S, Steczek L, Gotowicz K, et al. Preclinical evaluation of [18F]SYN1 and [18F]SYN2, novel radiotracers for PET myocardial perfusion imaging. EJNMMI Res. 2024. PMID: 38976101. doi:10.1186/s13550-024-01122-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。